Companies · Biotech / Pharma
Medford · Biotech / Pharma · refined from filed group “Other Technology”
Diligence memoA one-page analyst read on Greenlight Biosciences Inc. — recommendation, valuation, rhythm, risks.→Greenlight Biosciences Inc. has raised $179M over 5 rounds; too few niche peers to rank its valuation yet.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Greenlight Biosciences Inc. is one of 227 Biotech / Pharma companies tracked from Medford. By capital raised it ranks among the largest (ahead of 98% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Series D+ — a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.
Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 98% of sector peers (real $). Modeled value above 100% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $8.0M | 2013-07-29 | $36.6M | $269.5M | 85% |
| Series A | $7.0M | 2013-07-29 | $31.8M | $234.5M | 85% |
| Series B | $20.0M | 2015-06-01 | $111.2M | $735.9M | 85% |
| Series B | $10.0M | 2017-08-31 | $55.6M | $367.8M | 90% |
| Series B | $38.7M | 2018-12-07 | $215.3M | $1.4B | 90% |
| Series D+ | $102.5M | 2020-06-15 | $854.6M | $3.9B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Matthew Walker | — | 10 other | 2018-12 |
| Jonathan Fleming | — | 8 other | 2013-07 |
| Michael Liang | — | 8 other | 2020-06 |
| David Furneaux | — | 7 other | 2013-07 |
| Jason Dinges | — | 7 other | 2020-06 |
| Ganesh Kishore | — | 6 other | 2017-08 |
| Andrey Zarur | — | 5 other | 2013-07 |
| Eric O'Brien | — | 5 other | 2017-08 |
| Charles Cooney | — | 3 other | 2013-07 |
| Charles L. Cooney | — | 3 other | 2015-06 |
| Martha Schlicher | — | 3 other | 2018-12 |
| Neil Renninger | — | 3 other | 2013-07 |
| Greg Lucier | — | 1 other | 2013-07 |
| David L. Furneaux | — | — | 2015-06 |
| Ganesh L. Kishore | — | — | 2015-06 |
| James L. Swartz | — | — | 2015-06 |
| James Swartz | — | — | 2013-07 |
| Jonathan L. Fleming | — | — | 2015-06 |
| Marta L. Ortega-Valle | — | — | 2015-06 |
| Marta Ortega-Valle | — | — | 2017-08 |
| Neil L. Renninger | — | — | 2015-06 |
| William L. Blake | — | — | 2015-06 |
Greenlight Biosciences Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Lumicell, Inc. | Biotechnology | Series D+ | $331.1M | $1.7B | network2 shared operators · same stage |
| Alto Pharmacy Holdings, Inc. | Biotech / Pharma | Series D+ | $169.7M | $3.1B | same sector · same stage |
| Ventyx Biosciences, Inc. | Biotech / Pharma | Series D+ | $192.3M | $273.5M | same sector · same stage |
| Colossal Biosciences Inc. | Biotech / Pharma | Series D+ | $162.6M | $2.8B | same sector · same stage |
| Seismic Therapeutic, Inc. | Biotech / Pharma | Series D+ | $146.3M | $1.9B | same sector · same stage |
| Iterative Scopes, Inc. | Biotechnology | Series D+ | $172.1M | $3.6B | network1 shared operator · same stage |
| Vedanta Biosciences, Inc. | Biotech / Pharma | Series D+ | $240.3M | $2.0B | same sector · same stage |
| Elektrofi, Inc. | Biotechnology | Series D+ | $154.8M | $1.2B | network1 shared operator · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Greenlight Medical, Inc. | Healthtech | Seed | $32.6M | 92% |
| Light Bio, Inc. | Biotech / Pharma | Seed | $82.3M | 90% |
| ClearLight Biotechnologies, LLC | Biotech / Pharma | Seed | $113.9M | 89% |
| Greenlight Health Data Solutions, Inc. | Healthtech | Series A | $17.8M | 89% |
| Green Star Biosciences Inc. | Biotech / Pharma | Pre-Seed | $12.8M | 87% |
| Green Light Beverage, Inc. | Food & Beverage | Series B | $68.9M | 85% |
| growPack Bio LLC | Biotech / Pharma | Seed | $26.3M | 84% |
| Green Light Labs, Inc. | Software / Tech | Pre-Seed | $4.2M | 84% |
See where Greenlight Biosciences Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Greenlight Biosciences Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.